Cargando…

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers

Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resistance in these tumours, here we conduct a large-scale m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuster, Eugene F., Lopez-Knowles, Elena, Alataki, Anastasia, Zabaglo, Lila, Folkerd, Elizabeth, Evans, David, Sidhu, Kally, Cheang, Maggie Chon U., Tovey, Holly, Salto-Tellez, Manuel, Maxwell, Perry, Robertson, John, Smith, Ian, Bliss, Judith M., Dowsett, Mitch
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328947/ https://www.ncbi.nlm.nih.gov/pubmed/37419892 http://dx.doi.org/10.1038/s41467-023-39613-z

Ejemplares similares

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment
por: Schuster, Eugene F., et al.
Publicado: (2019)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas
por: López-Knowles, Elena, et al.
Publicado: (2016)

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)
por: Bliss, Judith M., et al.
Publicado: (2023)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
por: Smith, Ian, et al.
Publicado: (2020)

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer
por: Gao, Qiong, et al.
Publicado: (2018)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

Deficits in plasma oestradiol measurement in studies and management of breast cancer
por: Dowsett, Mitch, et al.
Publicado: (2005)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Who would have thought a single Ki67 measurement would predict long-term outcome?
por: Dowsett, Mitch, et al.
Publicado: (2009)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study
por: Bliss, Judith, et al.
Publicado: (2015)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification
por: Tovey, Holly, et al.
Publicado: (2019)

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition
por: López-Knowles, Elena, et al.
Publicado: (2014)

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018)

ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1
por: Dunbier, Anita K., et al.
Publicado: (2011)

Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women
por: McCormack, Valerie A, et al.
Publicado: (2009)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study
por: Schoemaker, M J, et al.
Publicado: (2014)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Genome-Wide Association Study of Circulating Estradiol, Testosterone, and Sex Hormone-Binding Globulin in Postmenopausal Women
por: Prescott, Jennifer, et al.
Publicado: (2012)

Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer
por: Jia, Xiao-qing, et al.
Publicado: (2015)

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
por: Haynes, Ben P., et al.
Publicado: (2021)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ivh51v3gru1o93vr05mnmubha3